Advertisement

Topics

Sanofi to develop Principia’s MS drug candidate in $805m deal

01:06 EST 10 Nov 2017 | Pharmaceutical Business Review

Sanofi has agreed to develop Principia Biopharma’s Bruton’s tyrosine kinase (BTK) inhibitor (PRN2246) for the treatment of multiple sclerosis (MS) and possibly other central nervous system (CNS) diseases.

Original Article: Sanofi to develop Principia’s MS drug candidate in $805m deal

NEXT ARTICLE

More From BioPortfolio on "Sanofi to develop Principia’s MS drug candidate in $805m deal"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...